Type 1 diabetes immunotherapy using polyclonal regulatory T cells
| العنوان: | Type 1 diabetes immunotherapy using polyclonal regulatory T cells |
|---|---|
| المؤلفون: | Amy L. Putnam, Qizhi Tang, Lisa M. Masiello, S. Alice Long, Vinh Son Nguyen, Angela P. Lares, Mark Fitch, Shipra Gupta, Weihong Liu, Stephen E. Gitelman, Jane H. Buckner, Mary Rieck, Michael R. Lee, Kelvin W. Li, Marc K. Hellerstein, Kevan C. Herold, Jeffrey A. Bluestone, Peter H. Sayre |
| المصدر: | Science translational medicine, vol 7, iss 315 Bluestone, JA; Buckner, JH; Fitch, M; Gitelman, SE; Gupta, S; Hellerstein, MK; et al.(2015). Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Science Translational Medicine, 7(315). doi: 10.1126/scitranslmed.aad4134. UCSF: Retrieved from: http://www.escholarship.org/uc/item/6664t6jzTest |
| بيانات النشر: | eScholarship, University of California, 2015. |
| سنة النشر: | 2015 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_treatment, T-Lymphocytes, Clinical Trials and Supportive Activities, chemical and pharmacologic phenomena, medicine.disease_cause, T-Lymphocytes, Regulatory, Autoimmune Disease, Medical and Health Sciences, Autoimmunity, Vaccine Related, Young Adult, Immune system, Clinical Research, Stem Cell Research - Nonembryonic - Human, medicine, Diabetes Mellitus, Humans, IL-2 receptor, Interleukin-7 receptor, Metabolic and endocrine, Autoimmune disease, Pediatric, 5.2 Cellular and gene therapies, business.industry, T-cell receptor, Diabetes, FOXP3, hemic and immune systems, General Medicine, Immunotherapy, Biological Sciences, medicine.disease, Stem Cell Research, Regulatory, Diabetes Mellitus, Type 1, Immunology, Female, Immunization, business, Type 1 |
| الوصف: | Type 1 diabetes (T1D) is an autoimmune disease that occurs in genetically susceptible individuals. Regulatory T cells (Tregs) have been shown to be defective in the autoimmune disease setting. Thus, efforts to repair or replace Tregs in T1D may reverse autoimmunity and protect the remaining insulin-producing β cells. On the basis of this premise, a robust technique has been developed to isolate and expand Tregs from patients with T1D. The expanded Tregs retained their T cell receptor diversity and demonstrated enhanced functional activity. We report on a phase 1 trial to assess safety of Treg adoptive immunotherapy in T1D. Fourteen adult subjects with T1D, in four dosing cohorts, received ex vivo-expanded autologous CD4(+)CD127(lo/-)CD25(+) polyclonal Tregs (0.05 × 10(8) to 26 × 10(8) cells). A subset of the adoptively transferred Tregs was long-lived, with up to 25% of the peak level remaining in the circulation at 1 year after transfer. Immune studies showed transient increases in Tregs in recipients and retained a broad Treg FOXP3(+)CD4(+)CD25(hi)CD127(lo) phenotype long-term. There were no infusion reactions or cell therapy-related high-grade adverse events. C-peptide levels persisted out to 2+ years after transfer in several individuals. These results support the development of a phase 2 trial to test efficacy of the Treg therapy. |
| وصف الملف: | application/pdf |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efa53972fd71c659bff6e8e38458a51bTest https://escholarship.org/uc/item/6664t6jzTest |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....efa53972fd71c659bff6e8e38458a51b |
| قاعدة البيانات: | OpenAIRE |
| الوصف غير متاح. |